くすりで肺がんを治す―過去・現在・未来

DOI HANDLE Web Site オープンアクセス

書誌事項

タイトル別名
  • Challenge to Cure Lung Cancer by Drug ; Past Present and Future
  • クスリ デ ハイ ガン オ ナオス : カコ ・ ゲンザイ ・ ミライ

この論文をさがす

抄録

Development of drug therapy for lung cancer originates in cytotoxic drugs. Following the report which indicate usefulness of cyclophosphamide for lung cancer, many cytotoxic drugs including cisplatin and taxanes were developed in the last century. However, their efficacy was modest and cure of metastatic lung cancer used to be an impossible dream. The paradigm shifted in 21st century due to a development of molecular targeted therapy followed by discovery of driver gene mutation. Today, selection of appropriate drug for patient with non-small cell lung cancer (NSCLC) is based on biomarker test including driver gene mutation, resulting in enhancement of therapeutic effects and avoidance of ineffective drugs. In addition, immune check point inhibitor was known to bring patientsʼ long term survival. Before cisplatin, 5-year survival rate of metastatic NSCLC used to be less than 1%. While, our present goal is to achieve longer than 50%. The era to cure lung cancer with drug therapy is just around the corner.

収録刊行物

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ